{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:27:16Z","timestamp":1793460436778,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Huntington Study group"},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Huntington\u2019s Disease (HD) is a progressive, fatal neurodegenerative condition. While generally considered for its devastating neurological phenotype, disturbances in other organ systems and metabolic pathways outside the brain have attracted attention for possible relevance to HD pathology, potential as therapeutic targets, or use as biomarkers of progression. In addition, it is not established how metabolic changes in the HD brain correlate to progression across the full spectrum of early to late-stage disease. In this pilot study, we sought to explore the metabolic profile across manifest HD from early to advanced clinical staging through metabolomic analysis by mass spectrometry in plasma and cerebrospinal fluid (CSF). With disease progression, we observed nominally significant increases in plasma arginine, citrulline, and glycine, with decreases in total and <jats:sc>d<\/jats:sc>-serine, cholesterol esters, diacylglycerides, triacylglycerides, phosphatidylcholines, phosphatidylethanolamines, and sphingomyelins. In CSF, worsening disease was associated with nominally significant increases in NAD<jats:sup>+<\/jats:sup>, arginine, saturated long chain free fatty acids, diacylglycerides, triacylglycerides, and sphingomyelins. Notably, diacylglycerides and triacylglyceride species associated with clinical progression were different between plasma and CSF, suggesting different metabolic preferences for these compartments. Increasing NAD<jats:sup>+<\/jats:sup> levels strongly correlating with disease progression was an unexpected finding. Our data suggest that defects in the urea cycle, glycine, and serine metabolism may be underrecognized in the progression HD pathology, and merit further study for possible therapeutic relevance.<\/jats:p>","DOI":"10.1038\/s41598-020-77526-9","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T11:16:29Z","timestamp":1606216589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington\u2019s disease for participants of varying functional disability: a pilot study"],"prefix":"10.1038","volume":"10","author":[{"given":"Andrew","family":"McGarry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gaughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Hackmyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lovett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Khadeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basant","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving W.","family":"Wainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruin","family":"Moaddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,24]]},"reference":[{"key":"77526_CR1","volume-title":"Huntington\u2019s Disease. Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease","author":"A McGarry","year":"2015","unstructured":"McGarry, A., Biglan, K. & Marshall, F. Huntington\u2019s Disease. Rosenberg\u2019s Molecular and Genetic Basis of Neurological and Psychiatric Disease (Elsevier, London, 2015)."},{"issue":"14","key":"77526_CR2","first-page":"2893","volume":"25","author":"JR Miller","year":"2016","unstructured":"Miller, J. R. et al. RNA-Seq of Huntington\u2019s disease patient myeloid cells 0reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum. Mol. Genet. 25(14), 2893\u20132904 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"77526_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fphys.2014.00380","volume":"5","author":"D Zielonka","year":"2014","unstructured":"Zielonka, D., Piotrowska, I., Marcinkowski, J. T. & Mielcarek, M. Skeletal muscle pathology in Huntington\u2019s disease. Front. Physiol. 5, 380 (2014).","journal-title":"Front. Physiol."},{"issue":"8","key":"77526_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0b013e318282514e","volume":"80","author":"SH Stuwe","year":"2013","unstructured":"Stuwe, S. H. et al. Hepatic mitochondrial dysfunction in manifest and premanifest Huntington\u2019s Disease. Neurology 80(8), 743\u2013746 (2013).","journal-title":"Neurology"},{"key":"77526_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jns.2016.02.018","volume":"362","author":"SMB Nielsen","year":"2016","unstructured":"Nielsen, S. M. B. et al. Liver function in Huntington\u2019s disease assessed by blood biochemical analyses in a clinical setting. J. Neurol. Sci. 362, 326\u2013332 (2016).","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"77526_CR6","doi-asserted-by":"publisher","first-page":"14275","DOI":"10.1038\/s41598-017-14290-3","volume":"7","author":"MK Bondulich","year":"2017","unstructured":"Bondulich, M. K. et al. Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington\u2019s disease mice. Sci. Rep. 7(1), 14275 (2017).","journal-title":"Sci. Rep."},{"issue":"3","key":"77526_CR7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/mdc3.12596","volume":"5","author":"CD Stephen","year":"2018","unstructured":"Stephen, C. D., Hung, J., Schifitto, G., Hersch, S. M. & Rosas, H. D. Electrocardiogram abnormalities suggest aberrant cardiac conduction in Huntington\u2019s Disease. Mov. Disord. Clin. Pract. 5(3), 306\u2013311 (2018).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"77526_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ana.410390317","volume":"39","author":"M Gu","year":"1996","unstructured":"Gu, M. et al. Mitochondrial defect in Huntington\u2019s disease caudate nucleus. Ann. Neurol. 39, 385\u2013389 (1996).","journal-title":"Ann. Neurol."},{"issue":"8","key":"77526_CR9","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1073\/pnas.0609833104","volume":"104","author":"J Powers","year":"2007","unstructured":"Powers, J. et al. Selective defect of in vivo glycolysis in early Huntington\u2019s disease striatum. Proc. Natl. Acad. Sci. USA 104(8), 2945\u20132949 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77526_CR10","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1212\/WNL.43.12.2689","volume":"43","author":"B Jenkins","year":"1993","unstructured":"Jenkins, B., Koroshetz, W., Beal, M. & Rosen, B. Evidence for impairment of energy metabolism in vivo in Huntington\u2019s disease using localized 1H NMR spectroscopy. Neurology. 43, 2689\u20132695 (1993).","journal-title":"Neurology."},{"issue":"8","key":"77526_CR11","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1007\/s12035-018-1448-3","volume":"56","author":"K Czubowicz","year":"2019","unstructured":"Czubowicz, K., J\u0119\u015bko, H., Wencel, P., Lukiw, W. J. & Strosznajder, R. P. The role of ceramide and sphingosine-1-phosphate in Alzheimer\u2019s disease and other neurodegenerative disorders. Mol. Neurobiol. 56(8), 5436\u20135455 (2019).","journal-title":"Mol. Neurobiol."},{"key":"77526_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnmol.2019.00068","volume":"12","author":"BD Paul","year":"2019","unstructured":"Paul, B. D. & Snyder, S. H. Impaired redox signaling in Huntington\u2019s Disease: therapeutic implications. Front. Mol. Neurosci. 12, 68 (2019).","journal-title":"Front. Mol. Neurosci."},{"issue":"9","key":"77526_CR13","doi-asserted-by":"publisher","first-page":"e0160384","DOI":"10.1371\/journal.pone.0160384","volume":"11","author":"NN Naseri","year":"2016","unstructured":"Naseri, N. N. et al. Novel metabolic abnormalities in the tricarboxylic acid cycle in peripheral cells from Huntington\u2019s Disease patients. PLoS ONE 11(9), e0160384 (2016).","journal-title":"PLoS ONE"},{"key":"77526_CR14","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1007\/s12035-018-1448-3","volume":"56","author":"K Czubowicz","year":"2019","unstructured":"Czubowicz, K., Jesko, H., Wencel, P., Lukiw, W. J. & Strosznajder, R. P. The role of ceramide and sphingosine-1-phosphate in Alzheimer\u2019s Disease and other neurodegenerative disorders. Mol. Neurobiol. 56, 5436\u20135455 (2019).","journal-title":"Mol. Neurobiol."},{"issue":"5","key":"77526_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.tips.2018.02.009","volume":"39","author":"AD Pardo","year":"2018","unstructured":"Pardo, A. D. & Maglione, V. The S1P axis: new exciting route for treating Huntington\u2019s disease. Trends Pharm. Sci. 39(5), 468\u2013480 (2018).","journal-title":"Trends Pharm. Sci."},{"issue":"2","key":"77526_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JHD-170273","volume":"7","author":"E Silajd\u017ei\u0107","year":"2018","unstructured":"Silajd\u017ei\u0107, E. & Bj\u00f6rkqvist, M. A critical evaluation of wet biomarkers for Huntington\u2019s Disease: current status and ways forward. J. Huntington\u2019s Dis. 7(2), 109\u2013135 (2018).","journal-title":"J. Huntington's Dis."},{"issue":"2","key":"77526_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/BF00343834","volume":"231","author":"G Oepen","year":"1970","unstructured":"Oepen, G., Cramer, H., Bernasconi, R. & Martin, P. Huntington\u2019s disease - imbalance of free amino acids in the cerebrospinal fluid of patients and offspring at-risk. Arch. Psychiatr. Nervenkr. 231(2), 131\u2013140 (1970).","journal-title":"Arch. Psychiatr. Nervenkr."},{"key":"77526_CR18","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1566-2772(03)00054-9","volume":"3","author":"LA Raymond","year":"2003","unstructured":"Raymond, L. A. Excitotoxicity in Huntington disease. Clin. Neurosci. Res. 3, 121\u2013128 (2003).","journal-title":"Clin. Neurosci. Res."},{"issue":"5","key":"77526_CR19","doi-asserted-by":"publisher","first-page":"e0127654","DOI":"10.1371\/journal.pone.0127654","volume":"10","author":"C-M Chen","year":"2015","unstructured":"Chen, C.-M. et al. High protein diet and Huntington\u2019s Disease. PLoS ONE 10(5), e0127654 (2015).","journal-title":"PLoS ONE"},{"key":"77526_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0022-510X(92)90191-M","volume":"108","author":"MF Beal","year":"1992","unstructured":"Beal, M. F. et al. Kynurenic acid concentrations are reduced in Huntington\u2019s disease cerebral cortex. J. Neurol. Sci. 108, 80\u201387. https:\/\/doi.org\/10.1016\/0022-510X(92)90191-M (1992).","journal-title":"J. Neurol. Sci."},{"key":"77526_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jnutbio.2015.12.001","volume":"31","author":"ML Cheng","year":"2016","unstructured":"Cheng, M. L., Chang, K. H., Wu, Y. R. & Chen, C. M. Metabolic disturbances in plasma as biomarkers for Huntington\u2019s disease. J. Nutr. Biochem. 31, 38\u201344 (2016).","journal-title":"J. Nutr. Biochem."},{"key":"77526_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11306-016-1084-8","volume":"12","author":"A Mastrokolias","year":"2016","unstructured":"Mastrokolias, A. et al. Integration of targeted metabolomics and transcriptomics identifies deregulation of phosphatidylcholine metabolism in Huntington\u2019s disease peripheral blood samples. Metabolomics 12, 137 (2016).","journal-title":"Metabolomics"},{"issue":"5","key":"77526_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/hmg\/ddl481","volume":"16","author":"MC Chiang","year":"2007","unstructured":"Chiang, M. C. et al. Dysregulation of C\/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington\u2019s disease. Hum. Mol. Genet. 16(5), 483\u2013498 (2007).","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"77526_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jacl.2009.11.003)","volume":"4","author":"RC Block","year":"2010","unstructured":"Block, R. C., Dorsey, E. R., Beck, C. A., Brenna, J. T. & Shoulson, I. Altered cholesterol and fatty acid metabolism in Huntington disease. J. Clin. Lipidol. 4(1), 17\u201323. https:\/\/doi.org\/10.1016\/j.jacl.2009.11.003) (2010).","journal-title":"J. Clin. Lipidol."},{"key":"77526_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00726-013-1493-1","volume":"45","author":"W Wang","year":"2013","unstructured":"Wang, W. et al. Glycine metabolism in animals and humans; implications for nutrition and health. Amino Acids 45, 463\u2013477 (2013).","journal-title":"Amino Acids"},{"issue":"12","key":"77526_CR26","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1007\/s00415-007-0611-y","volume":"254","author":"N Klepac","year":"2007","unstructured":"Klepac, N., Relja, M., Klepac, R., Hecimovic, T. B. & Trkulja, V. Oxidative stress parameters in plasma of Huntington\u2019s disease patients, asymptomatic Huntington\u2019s gene carriers and health subjects: a cross-sectional study. J. Neurol. 254(12), 1676\u20131683 (2007).","journal-title":"J. Neurol."},{"issue":"3","key":"77526_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/jnnp.44.3.258","volume":"44","author":"L Cunha","year":"1981","unstructured":"Cunha, L. et al. Homovanilic acid in Huntington\u2019s disease and Sydenham\u2019s chorea. J. Neurol. Neurosurg. Psychiatry 44(3), 258\u2013261 (1981).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"77526_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1471-4159.1992.tb09283.x","volume":"58","author":"MC Garrett","year":"1992","unstructured":"Garrett, M. C. & Soares-da-Silva, P. Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington\u2019s disease: evidence for an overactive dopaminergic brain transmission. J. Neurochem. 58(1), 101\u2013106 (1992).","journal-title":"J. Neurochem."},{"issue":"2","key":"77526_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1006\/exnr.1997.6428","volume":"144","author":"R Reilmsn","year":"1997","unstructured":"Reilmsn, R., Rolf, L. H. & Lange, W. L. Huntington\u2019s disease: N-methyl-d-aspartate receptor co-agonist glycine is increased in platelets. Exp. Neurol. 144(2), 416\u2013419 (1997).","journal-title":"Exp. Neurol."},{"key":"77526_CR30","volume-title":"Handbook of Cell Signaling","author":"MK Topham","year":"2010","unstructured":"Topham, M. K. & Prescott, S. M. Handbook of Cell Signaling 2nd edn. (Academic Press, Amsterdam, 2010).","edition":"2"},{"issue":"2","key":"77526_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov. Disord. 11(2), 136\u2013142. https:\/\/doi.org\/10.1002\/mds.870110204 (1996)","journal-title":"Mov. Disord."},{"key":"77526_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ab.2019.02.019","volume":"572","author":"TG Demarest","year":"2019","unstructured":"Demarest, T. G. et al. Assessment of NAD+ metabolism in human cultures, erythrocytes, cerebrospinal fluid and primate skeletal muscle. Anal. Biochem. 572, 1\u20138 (2019).","journal-title":"Anal. Biochem."},{"key":"77526_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1178646918776658","volume":"11","author":"AR Fricker","year":"2018","unstructured":"Fricker, A. R., Green, L. E., Jenkins, S. I. & Griffin, S. M. The influence of nicotinamide on health and disease in the central nervous system. Int. J. Tryptophan Res. 11, 1\u201311 (2018).","journal-title":"Int. J. Tryptophan Res."},{"issue":"8","key":"77526_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.tcb.2014.04.002","volume":"24","author":"IS Ima","year":"2014","unstructured":"Ima, I. S. & Guarente, L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24(8), 464\u2013471 (2014).","journal-title":"Trends Cell Biol."},{"key":"77526_CR35","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s11064-019-02809-1","volume":"44","author":"A Lloret","year":"2019","unstructured":"Lloret, A. & Beal, M. F. PGC-1\u03b1, sirtuins and PARPs in Huntington\u2019s Disease and other neurodegenerative conditions: NAD+ to rule them all. Neurochem. Res. 44, 2423\u20132434 (2019).","journal-title":"Neurochem. Res."},{"issue":"6","key":"77526_CR36","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/cr.2013.70","volume":"23","author":"A Herskovits","year":"2013","unstructured":"Herskovits, A. & Guarente, L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res. 23(6), 746\u2013758 (2013).","journal-title":"Cell Res."},{"issue":"7635","key":"77526_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nature21107","volume":"541","author":"CA Ross","year":"2017","unstructured":"Ross, C. A. & Truant, R. DNA repair: a unifying mechanism in neurodegeneration. Nature 541(7635), 34\u201335 (2017).","journal-title":"Nature"},{"key":"77526_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.tma.2018.08.003","volume":"2","author":"A Yahyah","year":"2018","unstructured":"Yahyah, A., Yumin, Q., Jun, T. & Evandro, F. F. Therapeutic potential of boosting NAD+ in aging ad age-related diseases. Transl. Med. Aging 2, 30\u201337 (2018).","journal-title":"Transl. Med. Aging"},{"issue":"18","key":"77526_CR39","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1089\/ars.2017.7145","volume":"28","author":"M Pehar","year":"2018","unstructured":"Pehar, M. et al. Nicotinamide adenine dinucleotide metabolism and neurodegeneration. Antioxid. Redox Signal. 28(18), 1652\u20131668 (2018).","journal-title":"Antioxid. Redox Signal."},{"key":"77526_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11302-006-9038-7","volume":"3","author":"H Friedrich","year":"2007","unstructured":"Friedrich, H. et al. Extracellular NAD and ATP: partners in immune cell modulation. Purinergic Signal. 3, 71\u201381 (2007).","journal-title":"Purinergic Signal."},{"key":"77526_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1196\/annals.1427.028","volume":"1147","author":"D Liu","year":"2008","unstructured":"Liu, D., Pitta, M. & Mattson, M. P. Preventing NAD+ depletion protects neurons against excitotoxicity. Ann. N. Y. Acad. Sci. 1147, 275 (2008).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"77526_CR42","doi-asserted-by":"crossref","unstructured":"Kumar, P., Jamwai, S. & Kumar, A. Management of HD: insight into molecular mechanisms and potential neuroprotective drug strategies. Pathology, Prevention and Therapeutics of Neurodegenerative Disease, pp. 197\u2013206 (2019)","DOI":"10.1007\/978-981-13-0944-1_18"},{"key":"77526_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fnins.2015.00469","volume":"9","author":"J Lewerenz","year":"2015","unstructured":"Lewerenz, J. & Maher, P. Chronic glutamate toxicity in neurodegenerative diseases\u2014what is the evidence?. Front. Neurosci. 9, 469 (2015).","journal-title":"Front. Neurosci."},{"key":"77526_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/859735","author":"A Durrant","year":"2014","unstructured":"Durrant, A. & Heresco-Levy, U. d-Serine in neuropsychiatric disorders: new advances. Adv. Psychiatry https:\/\/doi.org\/10.1155\/2014\/859735 (2014).","journal-title":"Adv. Psychiatry"},{"issue":"4","key":"77526_CR45","first-page":"779","volume":"20","author":"BM Gruber","year":"2013","unstructured":"Gruber, B. M. et al. Huntington\u2019 disease\u2014imbalance of amino acid levels in plasma of patients and mutation carriers. Ann. Agric. Environ. Med. 20(4), 779\u2013783 (2013).","journal-title":"Ann. Agric. Environ. Med."},{"issue":"8","key":"77526_CR46","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1073\/pnas.0609833104","volume":"104","author":"WJ Powers","year":"2007","unstructured":"Powers, W. J. et al. Selective defect of in vivo glycolysis in early Huntington\u2019s disease striatum. PNAS 104(8), 2945\u20132949. https:\/\/doi.org\/10.1073\/pnas.0609833104 (2007).","journal-title":"PNAS"},{"issue":"5","key":"77526_CR47","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.pnpbp.2005.04.023","volume":"29","author":"K Hashimoto","year":"2005","unstructured":"Hashimoto, K. et al. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 29(5), 767\u2013769. https:\/\/doi.org\/10.1016\/j.pnpbp.2005.04.023 (2005).","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"77526_CR48","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/0024-3205(88)90610-8","volume":"42","author":"E Bonilla","year":"1988","unstructured":"Bonilla, E., Prasad, A. L. N. & Arrieta, A. Huntington\u2019s disease: studies on brain free amino acids. Life Sci. 42(11), 1153\u20131158 (1988).","journal-title":"Life Sci."},{"issue":"3","key":"77526_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.arcmed.2007.11.011","volume":"39","author":"AM Esstrada Sanchez","year":"2008","unstructured":"Esstrada Sanchez, A. M., Tejia-Toiber, J. M. & Massieu, L. Excitotoxic neuronal death and the pathogenesis of Huntington\u2019s disease. Arch. Med. Res. 39(3), 265\u2013276 (2008).","journal-title":"Arch. Med. Res."},{"issue":"1","key":"77526_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0197-4580(89)80009-0","volume":"10","author":"R Elble","year":"1989","unstructured":"Elble, R., Giacobini, E. & Higgins, C. Choline levels are increased in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging 10(1), 45\u201350. https:\/\/doi.org\/10.1016\/S0197-4580(89)80009-0 (1989).","journal-title":"Neurobiol. Aging"},{"key":"77526_CR51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/j.1471-4159.2008.05641.x","volume":"107","author":"M Tachikawa","year":"2008","unstructured":"Tachikawa, M. et al. Cerebral creatinine clearance: involvement of transporter-mediated process. J. Neurochem. 107, 432\u2013442 (2008).","journal-title":"J. Neurochem."},{"issue":"6","key":"77526_CR52","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","volume":"89","author":"SM Hersch","year":"2017","unstructured":"Hersch, S. M. et al. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology 89(6), 594\u2013601 (2017)","journal-title":"Neurology"},{"issue":"4","key":"77526_CR53","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.neuro.2008.04.009","volume":"29","author":"S Zaja-Milatovic","year":"2008","unstructured":"Zaja-Milatovic, S. et al. Pharmacologic suppression of oxidative damage and dendritic degeneration following kainic acid-induced excitotoxicity in mouse cerebrum. Neurotoxicology 29(4), 621\u2013627. https:\/\/doi.org\/10.1016\/j.neuro.2008.04.009 (2008).","journal-title":"Neurotoxicology"},{"issue":"2","key":"77526_CR54","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pneurobio.2005.06.001","volume":"76","author":"FX Guix","year":"2005","unstructured":"Guix, F. X. et al. The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol. 76(2), 126\u2013152. https:\/\/doi.org\/10.1016\/j.pneurobio.2005.06.001 (2005).","journal-title":"Prog. Neurobiol."},{"issue":"4","key":"77526_CR55","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/01480540903130641","volume":"32","author":"M Swamy","year":"2009","unstructured":"Swamy, M., Sirajudeen, K. N. & Chandran, G. Nitric oxide (NO), citrulline-NO cycle enzymes, glutamine synthetase, and oxidative status in kainic acidmediated excitotoxicity in rat brain. Drug Chem Toxicol. 32(4), 326\u2013331. https:\/\/doi.org\/10.1080\/01480540903130641 (2009).","journal-title":"Drug Chem Toxicol."},{"issue":"4","key":"77526_CR56","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/0306-4522(95)00596-X","volume":"72","author":"PJ Norris","year":"1996","unstructured":"Norris, P. J. et al. Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington\u2019s disease. Neuroscience 72(4), 1037\u20131047 (1996).","journal-title":"Neuroscience"},{"issue":"1","key":"77526_CR57","doi-asserted-by":"publisher","first-page":"e0146480","DOI":"10.1371\/journal.pone.0146480","volume":"11","author":"R Nambron","year":"2016","unstructured":"Nambron, R. et al. A metabolic study of Huntington\u2019s disease. Plos one 11(1), e0146480. https:\/\/doi.org\/10.1371\/journal.pone.0146480 (2016).","journal-title":"Plos one"},{"key":"77526_CR58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0006-8993(00)02640-8","volume":"875","author":"AW Deckel","year":"2000","unstructured":"Deckel, A. W. et al. Dietary arginine alters time of symptom onset in Huntington\u2019s disease transgenic mice. Brain Res. 875, 187\u2013195 (2000).","journal-title":"Brain Res."},{"key":"77526_CR59","doi-asserted-by":"publisher","first-page":"43030","DOI":"10.1038\/srep43030","volume":"7","author":"DJ Skene","year":"2017","unstructured":"Skene, D. J. et al. Metabolic profiling of presymptomatic Huntington\u2019s disease sheep reveals novel biomarkers. Sci. Rep. 7, 43030. https:\/\/doi.org\/10.1038\/srep43030 (2017).","journal-title":"Sci. Rep."},{"key":"77526_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.01.004","author":"JFJ Bogie","year":"2020","unstructured":"Bogie, J. F. J., Haidar, M., Kooij, G. & Hendriks, J. J. A. Fatty acid metabolism in the progression and resolution of CNS disorders. Adv. Drug Deliv. Rev. https:\/\/doi.org\/10.1016\/j.addr.2020.01.004 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"77526_CR61","doi-asserted-by":"publisher","first-page":"e0146480","DOI":"10.1371\/journal.pone.0146480","volume":"11","author":"R Nambron","year":"2016","unstructured":"Nambron, R. et al. A metabolic study of Huntington\u2019s disease. PLoS ONE 11(1), e0146480. https:\/\/doi.org\/10.1371\/journal.pone.0146480 (2016).","journal-title":"PLoS ONE"},{"issue":"6","key":"77526_CR62","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.cmet.2019.03.004","volume":"29","author":"AA Polyzos","year":"2019","unstructured":"Polyzos, A. A. et al. Metabolic reprogramming in astrocytes distinguishes region-specific neuronal susceptibility in Huntington mice. Cell Metab. 29(6), 1258-1273.e11. https:\/\/doi.org\/10.1016\/j.cmet.2019.03.004 (2019).","journal-title":"Cell Metab."},{"key":"77526_CR63","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev-nutr-071811-150703","volume":"32","author":"H Wang","year":"2012","unstructured":"Wang, H. & Eckel, R. H. Lipoprotein lipase in the brain and nervous system. Annu. Rev. Nutr. 32, 147\u2013160 (2012).","journal-title":"Annu. Rev. Nutr."},{"key":"77526_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00010","author":"TJ Tracey","year":"2018","unstructured":"Tracey, T. J., Steyn, F. J., Wolvetang, E. J. & Ngo, S. T. Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease. Front. Mol. Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2018.00010 (2018).","journal-title":"Front. Mol. Neurosci."},{"issue":"1\u20132","key":"77526_CR65","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11010-017-3203-x","volume":"442","author":"J Choi","year":"2018","unstructured":"Choi, J. et al. Comprehensive analysis of phospholipids in the brain, heart, kidney, and liver: brain phospholipids are least enriched with polyunsaturated fatty acids. Mol. Cell Biochem. 442(1\u20132), 187\u2013201. https:\/\/doi.org\/10.1007\/s11010-017-3203-x (2018).","journal-title":"Mol. Cell Biochem."},{"issue":"1","key":"77526_CR66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1042\/BJ20071240","volume":"414","author":"M Villani","year":"2008","unstructured":"Villani, M. et al. Sphingomyelin synthases regulate production of diacylglycerol at the Golgi. Biochem. J. 414(1), 31\u201341. https:\/\/doi.org\/10.1042\/BJ20071240 (2008).","journal-title":"Biochem. J."},{"issue":"11","key":"77526_CR67","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3389\/fnins.2017.00698","volume":"19","author":"A Di Pardo","year":"2017","unstructured":"Di Pardo, A. et al. De novo synthesis of sphingolipids is defective in experimental models of Huntington\u2019s disease. Front. Neurosci. 19(11), 698 (2017).","journal-title":"Front. Neurosci."},{"key":"77526_CR68","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0006-8993(01)02028-5","volume":"895","author":"C Zimmermann","year":"2001","unstructured":"Zimmermann, C. et al. Lipopolysaccharide-induced ischemic tolerance is associated with increased levels of ceramide in brain and in plasma. Brain Res. 895, 59\u201365 (2001).","journal-title":"Brain Res."},{"issue":"5","key":"77526_CR69","doi-asserted-by":"publisher","first-page":"e62912","DOI":"10.1371\/journal.pone.0062912","volume":"8","author":"C M\u00fchle","year":"2013","unstructured":"M\u00fchle, C. et al. Characterization of acid sphingomyelinase activity in human cerebrospinal fluid. PLoS ONE 8(5), e62912 (2013).","journal-title":"PLoS ONE"},{"issue":"1","key":"77526_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/wnl.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson, I. & Fahn, S. Huntington disease: clinical care and evaluation. Neurology. 29(1), 1\u20133. https:\/\/doi.org\/10.1212\/wnl.29.1.1 (1979).","journal-title":"Neurology."},{"issue":"10","key":"77526_CR71","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/gerona\/glw046","volume":"71","author":"R Moaddel","year":"2016","unstructured":"Moaddel, R. et al. Plasma biomarkers of poor muscle quality in older men and women from the Baltimore longitudinal study of aging. J. Gerontol. Ser. A 71(10), 1266\u20131272 (2016).","journal-title":"J. Gerontol. Ser. A"},{"key":"77526_CR72","doi-asserted-by":"crossref","unstructured":"Semba R. D., et al. Serum lipids in adults with late age-related macular degeneration: a case-control study. Lip. Health Dis. 18, Article number: 7 (2019).","DOI":"10.1186\/s12944-018-0954-7"},{"key":"77526_CR73","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s00213-018-4992-7","volume":"235","author":"R Moaddel","year":"2018","unstructured":"Moaddel, R. et al. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacology. 235, 3017\u20133030 (2018).","journal-title":"Psychopharmacology."},{"key":"77526_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpba.2013.10.028","volume":"89","author":"Y Xie","year":"2014","unstructured":"Xie, Y. et al. Development and validation of a sensitive LC-MS\/MS method for the determination of d-serine in human plasma. J. Pharm. Biomed. Anal. 89, 1\u20135 (2014).","journal-title":"J. Pharm. Biomed. Anal."}],"updated-by":[{"DOI":"10.1038\/s41598-021-89167-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77526-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77526-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77526-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T23:45:12Z","timestamp":1670370312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77526-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,24]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77526"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77526-9","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-021-89167-7","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,24]]},"assertion":[{"value":"20 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-021-89167-7","URL":"https:\/\/doi.org\/10.1038\/s41598-021-89167-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20490"}}